You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The newly public company has attracted attention from both investors and competitors for its technology platform used in antibody discovery workflows.
The Boston-based firm is pursuing nanopore technology as a readout for its unique information-encoding format, which could help customers store vast amounts of data.
The Tokyo-based firm is looking to expand into the US market following a recent ¥700 million ($6.6 million) Series B financing round.
Driving the shift is a belief that standard STR testing is not always a reliable tool for determining complex family relationships.
The companies, which have been working since early 2019, will work together on Evonetix's first product, a desktop DNA synthesizer.
Horizons Ventures led the round, joined by Airbus Ventures, bringing the MIT spinout's fundraising total to date to more than $21 million.
he single-cell microbiome sequencing firm has raised a total of ¥1.5 billion in equity financing since its founding in 2018.
The cell analysis firm, which went public in July, saw service revenues fall 63 percent, offset by 17 percent growth in product revenues.
The Bay Area firm has built on its enzymatic barcoding technology to deliver a high-throughput, synthetic long-read library preparation technique.
The companies will use their agricultural and metagenomics expertise to develop products targeting biochemical processes specific to crop pests.
The New York-based multinational investment company will acquire Ancestry from current stakeholders Silver Lake, Spectrum Equity, Permira, and others.
The firm added $50 million from Casdin Capital, Danaher Life Sciences, and Agilent Technologies to its $38.5M Series B round announced in May 2019.
The research network said in a statement that precision breeding techniques are needed to achieve the UN's Sustainable Development Goals.
Cities and start-ups are pushing to incorporate SARS-CoV-2 wastewater monitoring into pandemic responses even as basic science researchers scramble to hammer out methods.
Tropic Bio will use its GEiGS (Gene Editing induced Gene Silencing) platform to develop desirable agricultural traits in BASF's strategic crop varieties.
The Emeryville, California-based instrument maker expects to raise $178.2 million after offering 8.1 million shares at $22 per share.
The US DOJ alleged that the company conspired to "artificially delay" ordering its MammaPrint test in order to circumvent Medicare's 14-day rule.
Dogs age more rapidly in their early years but then age more slowly later on, a DNA methylome analysis found, changing how dogs' ages are translated to human ages.
The Carlsbad, California-based company said that the contract — its third with the EPA — has a potential value of $25 million over five years.
The North Carolina State University team is working on scaling the technology further and may form a company to develop it commercially.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.
CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.
In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.